Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$12.88 USD

12.88
7,945,157

+0.02 (0.16%)

Updated Apr 22, 2024 04:00 PM ET

After-Market: $12.89 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (159 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates

by Zacks Equity Research

Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.

Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals

by Zacks Equity Research

Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

by Indrajit Bandyopadhyay

The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.

Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down

by Zacks Equity Research

Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.

J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug

by Zacks Equity Research

J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.

Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

by Zacks Equity Research

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.

Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.

TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up

by Zacks Equity Research

TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.

Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down

by Zacks Equity Research

TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

by Indrajit Bandyopadhyay

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study

by Zacks Equity Research

Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

TEVA Stock Declines Despite Q4 Earnings and Sales Beat

by Zacks Equity Research

TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.

TEVA Q4 Earnings & Sales Beat Estimates, Stock Rises

by Zacks Equity Research

TEVA beats earnings and sales for fourth-quarter 2020. It issues its financial guidance for 2021. Stock up

Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate

by Zacks Equity Research

Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

by Zacks Equity Research

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.

Is Teva Pharmaceutical (TEVA) a Good Stock to Pick Now?

by Zacks Equity Research

Is Teva Pharmaceutical (TEVA) a great pick from the value investor's perspective right now? Read on to know more.

Kinjel Shah headshot

6 Low Price-to-Book Value Stocks to Tap Market Boom

by Kinjel Shah

When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down

by Zacks Equity Research

TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.